Go to
current issue
-
Microbial ‘dark matter’ yields new antibiotic Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-28
Discover the world’s best science and medicine | Nature.com
-
Rewired proteostasis in KRAS inhibitor resistance Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-27
Discover the world’s best science and medicine | Nature.com
-
Antipsychotic displays dual GPCR binding mode Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-26
Discover the world’s best science and medicine | Nature.com
-
Drug delivery systems for CRISPR-based genome editors Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-18 Victoria Madigan, Feng Zhang, James E. Dahlman
-
Angering both sides of the drug pricing aisle Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-14
ICER’s incoming President, Sarah Emond, discusses drug pricing, multimillion dollar gene therapies and innovation incentives.
-
Artificial intelligence for natural product drug discovery Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-11 Michael W. Mullowney, Katherine R. Duncan, Somayah S. Elsayed, Neha Garg, Justin J. J. van der Hooft, Nathaniel I. Martin, David Meijer, Barbara R. Terlouw, Friederike Biermann, Kai Blin, Janani Durairaj, Marina Gorostiola González, Eric J. N. Helfrich, Florian Huber, Stefan Leopold-Messer, Kohulan Rajan, Tristan de Rond, Jeffrey A. van Santen, Maria Sorokina, Marcy J. Balunas, Mehdi A. Beniddir, Doris
-
Macrocycle drugs serve up new opportunities Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-11
Merck & Co.’s PCSK9 inhibitor MK-0616 showcases the potential of macrocycles as oral drugs for extracellular targets, even as several companies explore intracellular and macrocycle–drug conjugate possibilities.
-
Upcoming market catalysts in Q4 2023 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-08
Discover the world’s best science and medicine | Nature.com
-
Defining rare conditions in the era of personalized medicine Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-08 Daniel J. O’Connor, Michela Gabaldo, Annemieke Aartsma-Rus, Anneliene Hechtelt Jonker
The total number of rare conditions is debated, partly because of the variety of definitions of what constitutes rare. A broader consensus view of what rare means, based on improved understanding of individual group and patient clinicopathological characteristics, will help maximize the impact of technological advances in therapeutic development programmes.
-
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
Obesity drug scores landmark cardiovascular win Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
A step closer to in vivo editing of haematopoietic stem cells Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
FDA approves second RNA aptamer Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
Microbiome screening platform finds drugs for bugs Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
The next-generation CAR-T therapy landscape Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
LpxC inhibitor eliminates bacterial infections Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-04
Discover the world’s best science and medicine | Nature.com
-
Understanding class B GPCR agonist binding Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-04
Discover the world’s best science and medicine | Nature.com
-
Delivering mRNA to the lungs Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-04
Discover the world’s best science and medicine | Nature.com
-
Lipid metabolite triggers neural repair Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-04
Discover the world’s best science and medicine | Nature.com
-
AAV-based in vivo gene therapy for neurological disorders Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-01 Qinglan Ling, Jessica A. Herstine, Allison Bradbury, Steven J. Gray
-
Antimalarial drug discovery: progress and approaches Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-31 Jair L. Siqueira-Neto, Kathryn J. Wicht, Kelly Chibale, Jeremy N. Burrows, David A. Fidock, Elizabeth A. Winzeler
-
Therapeutic approaches for Duchenne muscular dystrophy Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-31 Thomas C. Roberts, Matthew J. A. Wood, Kay E. Davies
-
The company landscape for artificial intelligence in large-molecule drug discovery Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-29
Discover the world’s best science and medicine | Nature.com
-
Clipping cell-surface mucins in cancer by targeted degradation Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-25
Discover the world’s best science and medicine | Nature.com
-
A novel approach to boost drug development in paediatric oncology Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-22 Sam Daems, Hilde Stevens, Mathias Dewatripont, Hans-Georg Eichler, Michel Goldman
Despite major advances in cancer research, we are falling short in bringing innovative medicines to children with cancer. We propose a new business model to incentivize investors, private companies and public organizations to invest in drug development for paediatric cancers.
-
Targeting EMT in cancer through netrin-1 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-21
Discover the world’s best science and medicine | Nature.com
-
Chemoproteomic trailblazer advances covalent candidate into the clinic, pushes allosteric agenda Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-14
Vividion CEO Aleksandra Rizo discusses emerging lessons from the firm’s use of fragment-based phenotypic screening — including the potential for allosteric covalent drugs to drive different functional effects through a single binding site.
-
FDA approves first oral drug for postpartum depression, but rejects it for major depressive disorder Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-11
Discover the world’s best science and medicine | Nature.com
-
The therapeutic potential of targeting regulated non-apoptotic cell death Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-07 Kamyar Hadian, Brent R. Stockwell
-
The high, and redundant, cost of failure in cancer drug development Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-04
Discover the world’s best science and medicine | Nature.com
-
FDA approves long-acting RSV antibody Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-04
Discover the world’s best science and medicine | Nature.com
-
Alnylam scores big pharma support for angiotensinogen silencer Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-04
Discover the world’s best science and medicine | Nature.com
-
Strategies to therapeutically modulate cytokine action Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-04 Warren J. Leonard, Jian-Xin Lin
-
The potential of innovative trial design for efficiently evaluating repurposed drugs Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-03 James M. S. Wason, Oliver Bandmann
Innovative approaches to conducting proof-of-concept trials could accelerate the evaluation of repurposed drugs. Drawing lessons from repurposing efforts for COVID-19 therapies, here we present a vision for a drug repurposing platform that could maximize efficiency and improve patient outcomes for many different conditions.
-
Activating apoptosis in B cell lymphoma Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-02
Discover the world’s best science and medicine | Nature.com
-
Psychedelic treatment for anorexia Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-02
Discover the world’s best science and medicine | Nature.com
-
RNF41 reverses liver fibrosis Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-01
Discover the world’s best science and medicine | Nature.com
-
A specific biomarker for insoluble tau Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-01
Discover the world’s best science and medicine | Nature.com
-
Creating a path to splice-switching ASO therapies Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-01
Discover the world’s best science and medicine | Nature.com
-
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-08-01 Pavel Kolkhir, Cezmi A. Akdis, Mübeccel Akdis, Claus Bachert, Thomas Bieber, Giorgio Walter Canonica, Emma Guttman-Yassky, Martin Metz, Joaquim Mullol, Oscar Palomares, Harald Renz, Sonja Ständer, Torsten Zuberbier, Marcus Maurer
-
APOBEC3A drives resistance Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-31
Discover the world’s best science and medicine | Nature.com
-
Peptide vaccine turns up the heat in ALK-positive cancers Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-31
Discover the world’s best science and medicine | Nature.com
-
The R&D landscape for infectious disease vaccines Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-20
Discover the world’s best science and medicine | Nature.com
-
Topoisomerase II inhibitor cures trypanosome infections Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-19
Discover the world’s best science and medicine | Nature.com
-
Claudin-18.2 attracts the cancer crowd Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-17
Astellas’s claudin-18.2-targeted antibody zolbetuximab provides a benefit in hard-to-treat metastatic gastric cancer, and leads a multi-modality herd of contenders.
-
Disease modification in inflammatory skin disorders: opportunities and challenges Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-13 Thomas Bieber
-
Personalized cancer vaccines pass first major clinical test Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-12
Moderna, BioNTech and others hope that personalized cancer vaccines will soon live up to their potential — even as they work out the wrinkles for the best use of their platform technologies.
-
FDA new drug approvals in Q2 2023 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-11
Discover the world’s best science and medicine | Nature.com
-
Trends in the use of liquid biopsy in oncology Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-10
Discover the world’s best science and medicine | Nature.com
-
FDA approves first cell therapy for type 1 diabetes Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-07
Discover the world’s best science and medicine | Nature.com
-
Selective activation of Wnt ameliorates idiopathic pulmonary fibrosis Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-07
Discover the world’s best science and medicine | Nature.com
-
A non-covalent inhibitor with pan-KRAS potential Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-06
Discover the world’s best science and medicine | Nature.com
-
A strategy for small-molecule RNA degraders Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-05
Discover the world’s best science and medicine | Nature.com
-
Investigating the origins of recent pharmaceutical innovation Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-05
Discover the world’s best science and medicine | Nature.com
-
Treating cannabis use disorder Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-03
Discover the world’s best science and medicine | Nature.com
-
Extrahepatic oligonucleotide delivery Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-03
Discover the world’s best science and medicine | Nature.com
-
Towards polio eradication Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-03
Discover the world’s best science and medicine | Nature.com
-
Antibody offers broad alphavirus protection Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-07-03
Discover the world’s best science and medicine | Nature.com
-
Massive misuse of chemical probes undermines the utility of these tools Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-06-30
Discover the world’s best science and medicine | Nature.com
-
The case for cell-penetrating peptides Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-06-29
Incoming FogPharma CEO Mathai Mammen discusses the next frontier of cell-penetrating peptides, as the company advances a first candidate into the clinic to take on β-catenin.
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号